Literature DB >> 21225815

Systemic side effects of transtympanic steroids.

Ashley B Robey1, Trish Morrow, Gary F Moore.   

Abstract

OBJECTIVE: Review largest series of patients treated with transtympanic steroids, including outcomes, steroid dosing and adverse outcomes. Review first reported cases of systemic side effects from transtympanic steroids.
METHODS: A retrospective case series of 166 patients who underwent placement of transtympanic Silverstein tube with microwick for steroid administration was reviewed.
RESULTS: 5/166 patients developed systemic side effects, 9/166 patients developed local side effects. 48/166 (29%) of patients had a persistent perforation after therapy. The percent of patients with improvement as a function of symptoms: hearing loss 42%, tinnitus 56%, vertigo 68%, aural fullness 25% and dysequilibrium 66%.
CONCLUSIONS: While our study revealed a significant risk of persistent tympanic membrane perforation, the incidence of systemic and local side effects from transtympanic steroid administration is low.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21225815     DOI: 10.1002/lary.21684

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  3 in total

Review 1.  Intratympanic steroids as primary initial treatment of idiopathic sudden sensorineural hearing loss. The Hospital Universitario Ramón y Cajal experience and review of the literature.

Authors:  Tomás Labatut; María José Daza; Antonio Alonso
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-12-20       Impact factor: 2.503

2.  Radiologic anatomy of the round window relevant to cochlear implantation and inner ear drug delivery.

Authors:  Peter L Nguy; Sheela Saidha; Ann Jay; H Jeffrey Kim; Michael Hoa
Journal:  World J Otorhinolaryngol Head Neck Surg       Date:  2020-06-20

3.  Systemic effects of intratympanic dexamethasone therapy.

Authors:  Eva Novoa; Marcel Gärtner; Christoph Henzen
Journal:  Endocr Connect       Date:  2014-07-23       Impact factor: 3.335

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.